Zhejiang Huahai Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is FEBUXOSTAT, with a corresponding US DMF Number 26848.
Remarkably, this DMF maintains an Active status since its submission on February 13, 2013, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 15, 2014, and payment made on May 14, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II